FIELD: medicine.
SUBSTANCE: group of inventions relates to a method for improving functional capacity in a patient having multiple sclerosis, comprising administering to the patient an effective amount of anti-CD20 antibody, wherein the patient has improved functional capacity after administration and where the functional capacity improvement is maintained for at least 12 weeks; where anti-CD20 antibody contains: a) a heavy chain variable region comprising CDR1 having the amino acid sequence SEQ ID NO: 10, CDR2, having amino acid sequence SEQ ID NO: 11, and CDR3 having the amino acid sequence SEQ ID NO: 12, and b) a light chain variable region containing CDR1 having the amino acid sequence SEQ ID NO: 4, CDR2 having the amino acid sequence SEQ ID NO: 5, and CDR3, having amino acid sequence SEQ ID NO: 6. Group of inventions also relates to a method of reducing the average annual recurrence rate in a human patient having multiple sclerosis; kit for treating multiple sclerosis in a patient in accordance with said method.
EFFECT: group of inventions provides improved functional capacity in the patient suffering multiple sclerosis.
58 cl, 34 dwg, 14 tbl, 2 ex
Title | Year | Author | Number |
---|---|---|---|
METHODS AND MATERIALS FOR ASSESSMENT OF RESPONSE TO THERAPY AGAINST PLASMA-BLASTS AND PLASMA CELLS | 2017 |
|
RU2787629C2 |
COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY AGAINST CD20 | 2017 |
|
RU2782699C2 |
BISPECIFIC ANTIBODIES TO HUMAN CD20/HUMAN TRANSFERRIN RECEPTOR AND METHODS FOR THEIR USE | 2016 |
|
RU2753390C1 |
GM-CSF-NEUTRALIZING ANTIBODIES FOR USE IN TREATING RHEUMATOID ARTHRITIS OR AS ANALGESICS | 2014 |
|
RU2714919C2 |
RGMa BINDING PROTEIN AND ITS USE | 2016 |
|
RU2809500C2 |
ANTIRETROVIRAL DRUG AIMED AT HUMAN ENDOGENOUS RETROVIRUS | 2015 |
|
RU2689326C1 |
ANTIBODIES SPECIFIC TO MMP9 | 2015 |
|
RU2714043C2 |
A NEW COMBINATION FOR USE IN THE TREATMENT OF MALIGNANT NEOPLASMS | 2016 |
|
RU2742494C2 |
TYPES OF COMBINATION THERAPY USING CHIMERIC ANTIGEN RECEPTORS AND PD-1 INHIBITORS | 2017 |
|
RU2809160C2 |
CHIMERIC ANTIGENIC (CAR) RECEPTOR AGAINST CD123 FOR USE IN TREATING MALIGNANT TUMORS | 2015 |
|
RU2724999C2 |
Authors
Dates
2021-10-25—Published
2015-12-25—Filed